The role of PD-L1 as a ‘defensive’ immunomodulator is supported by studies showing that β-cells from patients with T1D or autoantibody positive individuals express higher levels of PD-L1 compared to normal controls (50, 65), and this expression was further induced in vitro by type I and II interferons (65). Here, CD274 is linked to type 1 diabetes mellitus.